Rexulti vs Latuda
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Rexulti | US Latuda | |
|---|---|---|
| Generic name | brexpiprazole | lurasidone |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Major depression (add-on), schizophrenia, agitation in dementia | Schizophrenia, bipolar depression |
| Category | Mental Health | Mental Health |
| Manufacturer | Otsuka/Lundbeck | Sunovion (Sumitomo) |
| Year approved | 2015 | 2010 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $170M | $85M |
| Common side effects | Weight gain, Restlessness, Drowsiness, Movement disorders | Sleepiness, Restlessness, Nausea, Movement problems |
Frequently asked questions
Is Rexulti or Latuda better?
Neither is universally "better." Rexulti (brexpiprazole) and Latuda (lurasidone) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rexulti and Latuda?
Rexulti is a Atypical Antipsychotic made by Otsuka/Lundbeck, while Latuda is a Atypical Antipsychotic made by Sunovion (Sumitomo). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rexulti has the larger estimated TV advertising budget of the two.